OncoMatch/Clinical Trials/NCT06315309
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
Is NCT06315309 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies ATG Combined with Tacrolimus and Mini Methotrexate for gvhd,acute.
Treatment: ATG Combined with Tacrolimus and Mini Methotrexate — The purpose of this study is to test whether the combination of the drugs called tacrolimus (Tac), methotrexate (MTX) and new dosing strategy of another drug called (rabbit Anti-thymocyte Globulin \[ATG\]) will help prevent the development and/or improve severity of acute and/or chronic GVHD.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Demographics
Prior therapy
Cannot have received: autologous hematopoietic stem cell transplant
Exception: allowed if > 3 months prior to enrollment
Autologous hematopoietic stem cell transplant < 3 months prior to enrollment
Cannot have received: allogeneic stem cell transplant
Previous allogeneic stem cell transplant
Lab requirements
Kidney function
creatinine clearance > 50 mL/min (Cockcroft-Gault formula, actual body weight)
Liver function
total bilirubin < 1.5x ULN (Gilbert's Disease allowed up to <3mg/dl); ALT/AST < 2.5x ULN
Cardiac function
Ejection fraction ≥ 45%
Cardiac function: Ejection fraction ≥ 45%; Calculated creatinine clearance greater than 50 mL/minute (using the Cockcroft-Gault formula and actual body weight); Liver function: total bilirubin < 1.5x the upper limit of normal and ALT/AST < 2.5x the upper normal limit. Patients who have been diagnosed with Gilbert's Disease are allowed to exceed the defined bilirubin value up to <3mg/dl.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06315309 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous hematopoietic stem cell transplant, allogeneic stem cell transplant disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 60 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify